Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5823728 | 0.95 | AKR1C3 (0.53) | AKR1C3AKR1C2PTGS2PTGS1HRH4 | |
| SCHEMBL5554578 | 0.94 | AKR1C3 (0.55) | AKR1C3AKR1C2PTGS2PTGS1HRH4 | |
| SCHEMBL5800372 | 0.93 | PTGS2 (0.53) | AKR1C3AKR1C2PTGS2PTGS1ABCB1 | |
| SCHEMBL5559508 | 0.91 | AKR1C3 (0.59) | AKR1C3AKR1C2PTGS2PTGS1HRH4 | |
| SCHEMBL5809154 | 0.91 | PTGS2 (0.68) | AKR1C3AKR1C2PTGS2PTGS1ABCB1 | |
| SCHEMBL5559100 | 0.91 | AKR1C3 (0.56) | AKR1C3AKR1C2PTGS2PTGS1HRH4 | |
| SCHEMBL6423575 | 0.90 | AKR1C3 (0.55) | AKR1C3AKR1C2PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL6461110 | 0.90 | PTGS2 (0.55) | AKR1C3AKR1C2PTGS2PTGS1HRH4 | |
| SCHEMBL5559675 | 0.89 | PTGS2 (0.52) | AKR1C3AKR1C2PTGS2PTGS1HRH4 | |
| SCHEMBL3002102 | 0.89 | AKR1C3 (0.72) | AKR1C3AKR1C2PTGS2PTGS1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643961-A4 | COX-2 AND FAAH INHIBITORS | MICROBIA INC (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1643961-A2 | COX-2 AND FAAH INHIBITORS | Microbia, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050032747-A1 | COX-2 and FAAH inhibitors | POLYMER CONCEPTS TECHNOLOGIES PBY, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005002525-A2 | COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032747-A1 | COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGS2 | AKR1C3 585/4885AKR1C2 342/4885PTGS2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.